A new class of biomaterial developed by Cornell researchers for an infectious disease nanovaccine effectively boosted immunity in mice with metabolic disorders linked to gut bacteria – a population that shows resistance to traditional flu and polio vaccines.
A biopharmaceutical company’s ability to improve society and bolster its humanitarian and philanthropic efforts are inextricably linked to its financial success. Merck Chairman and CEO Ken Frazier sought to emphasize just that point recently, speaking with Darden MBA students at the School’s Grounds in Rosslyn, VA.
In a national survey, hospital pharmacy managers report a lack of advance notice, frequent drug shortages, hoarding and even rationing. Improving the supply of generic medications and creating novel strategies to manage scarce drugs is needed.
Researchers from the Renaissance School of Medicine at Stony Brook University have identified a gene involved in the cancer stem cell (CSC) population of triple-negative breast cancer, a deadly form of disease. By blocking this gene’s action, tumor response to chemotherapy is improved.
Experimenting with mice, Johns Hopkins researchers report they have successfully used positron emission tomography (PET) scans to calculate in real time how much of an immunotherapy drug reaches a tumor and what parts of a cancer remain unaffected.
A frontline chemotherapy drug given to patients with pancreatic cancer is made less effective because similar compounds released by tumor-associated immune cells block the drug’s action, research led by the University of Michigan Rogel Cancer Center found.
Family planning for women might one day be as simple as putting on an earring. A report published recently in the Journal of Controlled Release describes a technique for administering contraceptive hormones through special backings on jewelry such as earrings, wristwatches, rings or necklaces.
Value in Health announced the publication of new research showing that pharmaceutical risk-sharing arrangements can mitigate uncertainty around the budget impact of drugs, but only when the type of arrangement matches the setting and type of uncertainty.
Value in Health announced today the publication of new research showing that Canadians believe drug coverage decision makers should prioritize safety, effectiveness, and strong evidence.
Increasingly aggressive insurance strategies have lowered the total costs and insurance costs of growth hormone drugs, but those savings are not being passed on to patients, according to new research to be presented Sunday at ENDO 2019, the Endocrine Society’s annual meeting in New Orleans, La.
Burosumab, a new injectable medicine to treat X-linked hypophosphatemia (XLH), an inherited form of rickets, demonstrates superior improvements in rickets and other outcomes compared with conventional therapy in an international, phase 3 clinical trial in children. Results from what investigators called the first head-to-head study comparing the new drug with conventional treatment for this rare disease will be presented Sunday at ENDO 2019, the Endocrine Society’s annual meeting in New Orleans, La.
In recent years, women who start taking bisphosphonates (BPs) to treat osteoporosis and prevent fracture have trended from younger to older and from having osteopenia to having osteoporosis, researchers report. The results of the study will be presented on Saturday at ENDO 2019, the Endocrine Society’s annual meeting in New Orleans, La.
Treating women who have thyroid antibodies, but normal thyroid function, with a medicine called Levothyroxine does not make them more likely to deliver a live baby, new research from the United Kingdom suggests. The research will be presented Saturday, March 23 at ENDO 2019, the Endocrine Society’s annual meeting in New Orleans, La., and published in The New England Journal of Medicine.
Simplifying medication regimens and tailoring glycemic targets in older adults with diabetes improves adherence and avoids treatment-related complications, according to a Clinical Practice Guideline issued today by the Endocrine Society. The Society debuted the guideline during a press conference on the opening day of ENDO 2019, its annual meeting in New Orleans, La.
Infections caused by drug-resistant bacteria are a global public health threat causing serious illness and even death. Strains of the bacterium Enterococcus faecium (E. faecium) are generally harmless in healthy people, but can be pathogenic in immunocompromised or severely ill patients.
From breakthroughs in regenerative medicine and medical imaging to advances in vaccine and drug development, Tulane University will showcase its latest research discoveries to biotechnology firms, venture capitalists, foundations and potential collaborators April 9-10 in New Orleans.
Drug therapy may effectively treat a potentially life-threatening condition associated with cirrhosis and other chronic liver diseases, according to a new study by Mayo Clinic researchers.
An inexpensive weight-loss drug approved 60 years ago for only short-term use also may be safe and effective for longer-term treatment, according to a study conducted by researchers at Wake Forest Baptist Health and the Patient Outcomes Research to Advance Learning (PORTAL) network. The study is published in today’s issue of the journal Obesity.
A new combination treatment aimed at resistant and recurrent low-grade gliomas slowed tumor growth and killed tumor cells in laboratory and mouse models.
Direct observations of the structure and catalytic mechanism of a prototypical kinase enzyme—protein kinase A or PKA—will provide researchers and drug developers with significantly enhanced abilities to understand and treat fatal diseases and neurological disorders such as cancer, diabetes, and cystic fibrosis. The discovery was made by an international team of researchers using macromolecular neutron crystallography at the Department of Energy’s Oak Ridge National Laboratory and the Institut Laue-Langevin in Grenoble, France.
The American Association of Nurse Anesthetists (AANA) has published a comprehensive update to its Standards for Nurse Anesthesia Practice, the foundation of Certified Registered Nurse Anesthetist (CRNA) care delivery.
A new model for intensive care, developed by Rutgers and RWJBarnabas Health System, can help identify preventable – and previously overlooked – factors that often send chronically ill patients to the intensive care unit (ICU).
The Blue Ridge Poison Center (BRPC) at the University of Virginia Health System is commemorating National Poison Prevention Week from March 17-23 by focusing on protecting your prescription medicines from falling into the wrong hands.
ZULRESSO, developed by Sage Therapeutics, is the first and only treatment specifically indicated to treat postpartum depression in women. UNC School of Medicine’s Samantha Meltzer-Brody, MD, MPH, was the principal investigator for three clinical trials showing rapid-reduction in depressive symptoms, and says the approval marks a major step forward in women’s healthcare.
Irvine, Calif., March 19, 2019 — Bernadette Boden-Albala, Dr.P.H. – a renowned researcher and administrator whose efforts to reduce health disparities for America’s disadvantaged became a blueprint for community-based stroke and heart disease prevention – has been named director and founding dean of the University of California, Irvine’s planned School of Population Health, effective July 1.
The Valley Hospital participated in a landmark clinical trial that evaluated the ability of a novel, fully absorbable antibacterial envelope – the Medtronic TYRX™ Absorbable Antibacterial Envelope – to reduce infections associated with cardiac implantable electronic devices (CIEDs). The study found positive results and demonstrated that the envelope reduced the risk of major infection by 40 percent, and pocket infection by 61 percent, in patients at increased risk for infections receiving CIEDs, compared to standard-of-care pre-operative antibiotics.
The Endocrine Society has hired Michel Y. Farhat, Ph.D.—a seasoned executive with more than 20 years of experience in the pharmaceutical industry—to serve as its Chief Strategic Partnerships Officer.
EB 2019, to be held April 6–9 at the Orange County Convention Center in Orlando, is the annual meeting of five scientific societies, bringing together more than 12,000 scientists and 25 guest societies in one interdisciplinary community.
The U.S. Food and Drug Administration’s approval today of atezolizumab (Tecentriq®, Genentech) in combination with chemotherapy (carboplatin and etoposide) for the initial treatment of extensive-stage small cell lung cancer (SCLC) marks the end of numerous failed attempts to improve survival for those with the deadly disease.
Common medications prescribed to treat heartburn, acid reflux and ulcers are linked to increased risks for kidney failure and chronic kidney disease, found a recent University at Buffalo study.
Stanley Chetcuti, M.D., co-author on the Evolut trial of low-risk TAVR/ interventional cardiologist at Michigan Medicine (University of Michigan) comments on importance of both late-breaking clinical trials re: low-risk TAVR (Evolut and Partner 3) at the American College of Cardiology Scientific Sessions.
A Cleveland Clinic-led research team has found that using an absorbable, antibiotic-eluting envelope when implanting cardiac devices like pacemakers and defibrillators can cut the rate of major infections by 40 percent. The research was presented today at the American College of Cardiology’s 68th Annual Scientific Session and simultaneously published in the New England Journal of Medicine. It will also be presented tomorrow at the European Heart Rhythm Association 2019 Congress.
S. Chris Malaisrie, MD, a cardiac surgeon at Northwestern Memorial Hospital, associate professor of surgery (cardiac surgery) at Northwestern University Feinberg School of Medicine and co-chair of the PARTNER 3 case review board, is available to comment on PARTNER 3.
The 33 million people with atrial fibrillation worldwide not only suffer from bothersome symptoms, but also face a fivefold increased risk of stroke and a twofold increased risk of death. Research teams led by Mayo Clinic published three connected studies on Friday, March 15, clarifying the benefits of catheter ablation versus rate- or rhythm-control medications to treat atrial fibrillation.
Atrial fibrillation is a common arrhythmia that affects an estimated 30 million people worldwide. New research shows that catheter ablation, a common cardiovascular procedure, appears no more effective than drug therapy to prevent strokes, deaths and other complications in patients with atrial fibrillation. But patients who receive catheter ablation experience much greater symptom relief and long-term improvements in quality of life. And they have fewer recurrences of their atrial fibrillation and fewer hospitalizations than those who receive only drugs. You can learn more about this new research in the March 15 issue of JAMA.
New findings, published today in AACC’s Clinical Chemistry journal, add to a growing body of evidence suggesting that no legal driving limit for cannabis can catch impaired recreational users without unfairly penalizing unimpaired regular or medicinal users.
A biomedical engineer at Washington University in St. Louis is developing a therapeutic option that would prevent opiates from crossing the blood-brain barrier, preventing the high abusers seek.
A synthetic DNA structure was used as bait to capture nuclear proteins, revealing previously unknown role of HNRNPD in the cellular response to DNA damage.
The Jefferson College of Pharmacy has announced a new master’s degree in Population Health Pharmacy. One of the first of its kind, the Master’s in Population Health Pharmacy focuses on the impact of health determinants on outcomes associated with medication use.
The first arm of a phase II clinical trial by a research team at Georgetown University Medical Center testing the use of nilotinib in patients with Parkinson’s disease demonstrates precisely how the agent increases levels of dopamine in the brains of study participants.
There is no such thing as TMI (too much information) when it comes to communicating facts about your health with your physician anesthesiologist before surgery or a medical procedure. You might not think taking ginkgo biloba for memory, using medical marijuana for pain, smoking or snoring are relevant, but these supplements, drugs and conditions are among the eight things you should disclose for your own safety, notes the American Society of Anesthesiologists (ASA).
Researchers at Vanderbilt University Medical Center and colleagues have identified a gene that increases the risk for a severe and potentially life-threatening reaction to the commonly prescribed antibiotic vancomycin. Routine testing for this gene could improve patient safety and reduce unnecessary avoidance of other antibiotics, they reported in the Journal of Allergy and Clinical Immunology.
An international panel of the foremost researchers on infectious disease and antimicrobials has formed new guidelines on the use of polymyxins, a class of antibiotics employed as a last resort to treat deadly, drug-resistant bacteria.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right